ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ÌÇÐÄ´«Ã½

Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.

ÌÇÐÄ´«Ã½

Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study. Litton, J., Beck, J., Jones, J. M., Andersen, J., Blum, J., Mina, L. A., Brig, R., Danso, M. A., Yuan, Y., Abbattista, A., Noonan, K., Chakrabarti, J., Czibere, A., Symmans, W., Telli, M. L. LIPPINCOTT WILLIAMS & WILKINS. 2021

View details for